Page 112 - Read Online

Zhang et al. Hepatoma Res 2020;6:40 I http://dx.doi.org/10.20517/2394-5079.2020.20 Page 11 of 12

86. Yang JY, Cao DY, Xue Y, Yu ZC, Liu WC. Improvement of dendritic-based vaccine efficacy against hepatitis B virus-related
hepatocellular carcinoma by two tumor-associated antigen gene-infected dendritic cells. Hum Immunol 2010;71:255-62.
87. Shi M, Qian S, Chen WW, Zhang H, Zhang B, et al. Hepatitis B virus (HBV) antigen-pulsed monocyte-derived dendritic cells from HBV-
associated hepatocellular carcinoma patients significantly enhance specific T cell responses in vitro. Clin Exp Immunol 2007;147:277-86.
88. Guo DW, Zhang SY, Hou XZ, Li HW, Jiang XF, et al. Glypican3 in genetically modified human monocyte-derived dendritic cells induced
specific cytotoxity against glypican3 overexpressing human hepatocellular carcinoma cells in vitro. Saudi Med J 2008;29:1235-40.
89. Tada F, Abe M, Hirooka M, Ikeda Y, Hiasa Y, et al. Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in
patients with hepatocellular carcinoma. Int J Oncol 2012;41:1601-9.
90. Lee JH, Lee Y, Lee M, Heo MK, Song JS, et al. A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic
cells in patients with hepatocellular carcinoma. Br J Cancer 2015;113:1666-76.
91. Ge C, Xing Y, Wang Q, Xiao W, Lu Y, et al. Improved efficacy of therapeutic vaccination with dendritic cells pulsed with tumor cell
lysate against hepatocellular carcinoma by introduction of 2 tandem repeats of microbial HSP70 peptide epitope 407-426 and OK-432. Int
Immunopharmacol 2011;11:2200-7.
92. Nakamoto Y, Mizukoshi E, Kitahara M, Arihara F, Sakai Y, et al. Prolonged recurrence-free survival following OK432-stimulated
dendritic cell transfer into hepatocellular carcinoma during transarterial embolization. Clin Exp Immunol 2011;163:165-77.
93. Maeda Y, Yoshimura K, Matsui H, Shindo Y, Tamesa T, et al. Dendritic cells transfected with heat-shock protein 70 messenger RNA for
patients with hepatitis C virus-related hepatocellular carcinoma: a phase 1 dose escalation clinical trial. Cancer Immunol Immunother
2015;64:1047-56.
94. Chen C, Ma YH, Zhang YT, Zhang F, Zhou N, et al. Effect of dendritic cell-based immunotherapy on hepatocellular carcinoma: a
systematic review and meta-analysis. Cytotherapy 2018;20:975-89.
95. Ninomiya T, Akbar SM, Masumoto T, Horiike N, Onji M. Dendritic cells with immature phenotype and defective function in the
peripheral blood from patients with hepatocellular carcinoma. J Hepatol 1999;31:323-31.
96. Chen S, Akbar SM, Tanimoto K, Ninomiya T, Iuchi H, et al. Absence of CD83-positive mature and activated dendritic cells at cancer
nodules from patients with hepatocellular carcinoma: relevance to hepatocarcinogenesis. Cancer Lett 2000;148:49-57.
97. Iwashita Y, Goto S, Tahara K, Kawano K, Chen CL, et al. Potent stimuli combined with lipopolysaccaride and IFNgamma may improve
immunotherapy against HCC by increasing the maturation and subsequent immune response of the dendritic cells. Cancer Biother
Radiopharm 2003;18:1-6.
98. Gonzalez-Carmona MA, Lukacs-Kornek V, Timmerman A, Shabani S, Kornek M, et al. CD40ligand-expressing dendritic cells induce
regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo. Hepatology 2008;48:157-68.
99. Chan RC, Pang XW, Wang YD, Chen WF, Xie Y. Transduction of dendritic cells with recombinant adenovirus encoding HCA661
activates autologous cytotoxic T lymphocytes to target hepatoma cells. Br J Cancer 2004;90:1636-43.
100. Peng W, Zhao G, Ma Y, Yu H, Wang X. Dendritic cells transfected with PEG10 recombinant adenovirus elicit anti-tumor immune
response in vitro and in vivo. Vaccine 2011;29:3501-6.
101. Vogt A, Sievers E, Lukacs-Kornek V, Decker G, Raskopf E, et al. Improving immunotherapy of hepatocellular carcinoma (HCC) using
dendritic cells (DC) engineered to express IL-12 in vivo. Liver Int 2014;34:447-61.
102. Choi YJ, Park SJ, Park YS, Park HS, Yang KM, et al. EpCAM peptide-primed dendritic cell vaccination confers significant anti-tumor
immunity in hepatocellular carcinoma cells. PLoS One 2018;13:e0190638.
103. Yang X, Zhu H, Hu Z. Dendritic cells transduced with TEM8 recombinant adenovirus prevents hepatocellular carcinoma angiogenesis
and inhibits cells growth. Vaccine 2010;28:7130-5.
104. Su H, Li B, Zheng L, Wang H, Zhang L. Immunotherapy based on dendritic cells pulsed with CTPFoxM1 fusion protein protects against
the development of hepatocellular carcinoma. Oncotarget 2016;7:48401-11.
105. Zerbini A, Pilli M, Fagnoni F, Pelosi G, Pizzi MG, et al. Increased immunostimulatory activity conferred to antigen-presenting cells by
exposure to antigen extract from hepatocellular carcinoma after radiofrequency thermal ablation. J Immunother 2008;31:271-82.
106. Hu Z, Chen J, Zhou S, Yang N, Duan S, et al. Mouse IP-10 gene delivered by folate-modified chitosan nanoparticles and dendritic/tumor
cells fusion vaccine effectively inhibit the growth of hepatocellular carcinoma in mice. Theranostics 2017;7:1942-52.
107. Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for
hepatocellular carcinoma. Gastroenterology 2015;148:1383-91.e6.
108. Jung NC, Lee JH, Choi HJ, Hwang SU, Song JY, et al. Dendritic cell immunotherapy combined with cytokine-induced killer cells
effectively suppresses established hepatocellular carcinomas in mice. Immunol Invest 2016;45:553-65.
109. Chen BA, Li M, Sun ZY, Li CP, Gao C, et al. Killing activity in DC and CIK co-culture against hepatocarcinoma cells. Zhongguo Shi Yan
Xue Ye Xue Za Zhi 2006;14:543-6.
110. Qiu Y, Xu MB, Yun MM, Wang YZ, Zhang RM, et al. Hepatocellular carcinoma-specific immunotherapy with synthesized alpha1,3-
galactosyl epitope-pulsed dendritic cells and cytokine-induced killer cells. World J Gastroenterol 2011;17:5260-6.
111. Niu LZ, Li JL, Zeng JY, Mu F, Liao MT, et al. Combination treatment with comprehensive cryoablation and immunotherapy in metastatic
hepatocellular cancer. World J Gastroenterol 2013;19:3473-80.
112. Yoon JS, Song BG, Lee JH, Lee HY, Kim SW, et al. Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma:
a propensity score-matched analysis of real-world data. BMC Cancer 2019;19:523.
113. Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, et al. Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for
hepatocellular carcinoma: an extended 5-year follow-up. Cancer Immunol Immunother 2019;68:23-32.
114. Guo W, Liu L, Wu D. Dendritic cell-cytokine induced killer cell immunotherapy combined with transcatheter arterial chemoembolization